Results 21 to 30 of about 82,196 (246)

Buprenorphine added on brief cognitive behavioral therapy for treatment of methamphetamine use disorder [PDF]

, 2018
Background: Methamphetamine (MA) use remains a major public health concern around the world. Recent findings suggest that buprenorphine may be helpful for cocaine use reduction. Moreover, animal studies described reduced dopamine peak effect following MA
Dean AJ, Hassani-Abharian P, Hollister LE, Karimlou M, Kirchmayer U, Kosten TR, Mello NK, Nejati V, Raistrick D, Rothenberg JL,     +10 more
core   +1 more source

A comparative study of intrathecal and epidural buprenorphine using combined spinal-epidural technique for caesarean section

Indian Journal of Anaesthesia, 2010
Neuraxial opioids provide excellent analgesia intraoperatively and postoperatively while allowing early ambulation of the patient by sparing sympathetic and motor nerves. A prospective, randomised double blind study was conducted involving 90 patients of
Shaloo Ipe, Sara Korula, Sreelatha Varma, Grace Maria George, Saramma P Abraham, Leena Rachel Koshy   +5 more
doaj   +1 more source

Old Drugs for JAK-STAT Pathway Inhibition in COVID-19 [PDF]

, 2020
The pandemic threat of COVID-19 with more than 37 million cases in which about 5 percent entering critical stage characterized by cytokine storm and hyperinflammatory condition, the state more often leads to admission to intensive care unit with rapid mortality.
arxiv   +1 more source

Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs

Substance Abuse Treatment, Prevention, and Policy, 2022
Background and aims In the United States, access to buprenorphine remains low and disparities regarding who receives treatment have emerged. Federal laws have regulated buprenorphine delivery, ultimately limiting its implementation more broadly.
Barrot H. Lambdin, David Kan, Alex H. Kral   +2 more
doaj   +1 more source

Buprenorphine versus dihydrocodeine for opiate detoxification in primary care: a randomised controlled trial [PDF]

, 2007
Background Many drug users present to primary care requesting detoxification from illicit opiates. There are a number of detoxification agents but no recommended drug of choice. The purpose of this study is to compare buprenorphine with dihydrocodeine
A Davies, A Glanz, A Masson, A Nigam, C de Wet, Charlotte NE Tompkins, Clive E Adams, D van der Windt, D Zador, E Ward, G Fischer, H Swadi, J Banbery, J Hetherton, J Lowinson, J MacLeod, J Seifert, J Strang, K Carrol, K Fairhurst, L Cheskin, L Sheard, Laura Sheard, M Ashton, M Gossop, N Lintzeris, N Seivewright, N Wright, Nat MJ Wright, National Treatment Agency, Nicola S Oldham, P O'Connor, P Pani, R Horton, R Johnson, R Mattick, R Robertson, R White, Royal College of General Practitioners, S Petitjean, S Simoens, S Vanichseni, T Kosten, Victoria L Allgar, W Bickel, W Ling   +45 more
core   +3 more sources

The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) project: An open-label pragmatic randomised control trial comparing the efficacy of differing therapeutic agents for primary care detoxification from either street heroin or methadone [ISRCTN07752728] [PDF]

, 2004
BACKGROUND: Heroin is a synthetic opioid with an extensive illicit market leading to large numbers of people becoming addicted. Heroin users often present to community treatment services requesting detoxification and in the UK various agents are used ...
A Ritter, Advisory Council on the Misuse of Drugs, AH Masson, AK Nigam, Charlotte NE Tompkins, Clive E Adams, E Goddard, Great Britain Department of Health, Great Britain Government Statistical Service, Home Office, J Lowinson, J Strang, J Strang, L San, Laura Sheard, LJ Cheskin, M Ramsay, N Linteris, N Seivewright, Nat MJ Wright, Nicola S Oldham, PG O'Connor, Royal Pharmaceutical Society of Great Britain, WK Bickel   +22 more
core   +3 more sources

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report [PDF]

Mental Health Clinician, 2021
Background Buprenorphine is a partial mu-opioid receptor agonist approved for the treatment of opioid dependence. The risk of withdrawal symptoms and wait time required to safely initiate buprenorphine provides challenges to both patients and providers ...
Menard Shannon PharmD, Jhawar Archana PharmD, BCPP   +1 more
doaj   +1 more source

Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin‐evoked dopamine release in rats

Neuropsychopharmacology Reports, 2020
Aims The United States of America is currently in an opioid epidemic. Heroin remains the most lethal opioid option with its death rate increasing by over 500% in the last decade.
Dominic P. Isaacs, Ryan P. Leman, Thomas J. Everett, Hendrick Lopez‐Beltran, Lindsey R. Hamilton, Erik B. Oleson   +5 more
doaj   +1 more source

Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine‐maintained heroin users [PDF]

Addiction Biology, 2014
AbstractIn spite of the clinical utility of buprenorphine, parenteral abuse of this medication has been reported in several laboratory investigations and in the real world. Studies have demonstrated lower abuse liability of the buprenorphine/naloxone combination relative to buprenorphine alone.
Verena E. Metz, Shanthi Mogali, Suzanne K. Vosburg, Jeanne M. Manubay, Jermaine D. Jones, Maria A. Sullivan, Sandra D. Comer   +6 more
openaire   +2 more sources

The challenge of perioperative pain management in opioid-tolerant patients [PDF]

, 2017
The increasing number of opioid users among chronic pain patients, and opioid abusers among the general population, makes perioperative pain management challenging for health care professionals.
Bifulco, F, Coluzzi, Flaminia, Corcione, A., Cuomo, A, Dauri, M, Leonardi, C, Melotti, Rm, Natoli, S, Romualdi, P, Savoia, G   +9 more
core   +6 more sources